🚀 VC round data is live in beta, check it out!
MannKind Valuation Multiples
Discover revenue and EBITDA valuation multiples for MannKind and similar public comparables like Arbutus Biopharma, ARS Pharmaceuticals, Bicara Therapeutics, OPKO Health and more.
MannKind Overview
About MannKind
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Founded
1991
HQ
Employees
407
Website
Sectors
Financials (LTM)
EV
$766M
MannKind Financials
MannKind reported last 12-month revenue of $375M.
In the same LTM period, MannKind generated $319M in gross profit and $4M in net income.
Revenue (LTM)
MannKind P&L
In the most recent fiscal year, MannKind reported revenue of $349M and EBITDA of $52M.
MannKind expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $375M | XXX | $349M | XXX | XXX | XXX |
| Gross Profit | $319M | XXX | $261M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | — | XXX | $52M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $4M | XXX | $6M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | — | — | $280M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
MannKind Stock Performance
MannKind has current market cap of $906M, and enterprise value of $766M.
Market Cap Evolution
MannKind's stock price is $2.95.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $766M | $906M | 0.0% | XXX | XXX | XXX | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMannKind Valuation Multiples
MannKind trades at 2.0x EV/Revenue multiple, and 14.9x EV/EBITDA.
EV / Revenue (LTM)
MannKind Financial Valuation Multiples
As of March 21, 2026, MannKind has market cap of $906M and EV of $766M.
Equity research analysts estimate MannKind's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MannKind has a P/E ratio of 229.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $906M | XXX | $906M | XXX | XXX | XXX |
| EV (current) | $766M | XXX | $766M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 14.9x | XXX | XXX | XXX |
| EV/EBIT | 18.8x | XXX | 16.4x | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | 2.9x | XXX | XXX | XXX |
| P/E | 229.7x | XXX | 154.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 55.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MannKind Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
MannKind Margins & Growth Rates
MannKind's revenue in the last 12 month grew by 28%.
MannKind's revenue per employee in the last FY averaged $0.9M.
MannKind Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 28% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (34%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 19% | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 62% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
MannKind Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Arbutus Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| ARS Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Bicara Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| OPKO Health | XXX | XXX | XXX | XXX | XXX | XXX |
| UroGen Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MannKind M&A Activity
MannKind acquired XXX companies to date.
Last acquisition by MannKind was on XXXXXXXX, XXXXX. MannKind acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by MannKind
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMannKind Investment Activity
MannKind invested in XXX companies to date.
MannKind made its latest investment on XXXXXXXX, XXXXX. MannKind invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by MannKind
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MannKind
| When was MannKind founded? | MannKind was founded in 1991. |
| Where is MannKind headquartered? | MannKind is headquartered in United States. |
| How many employees does MannKind have? | As of today, MannKind has over 407 employees. |
| Who is the CEO of MannKind? | MannKind's CEO is Michael E. Castagna. |
| Is MannKind publicly listed? | Yes, MannKind is a public company listed on Nasdaq. |
| What is the stock symbol of MannKind? | MannKind trades under MNKD ticker. |
| When did MannKind go public? | MannKind went public in 2004. |
| Who are competitors of MannKind? | MannKind main competitors are Arbutus Biopharma, ARS Pharmaceuticals, Bicara Therapeutics, OPKO Health. |
| What is the current market cap of MannKind? | MannKind's current market cap is $906M. |
| What is the current revenue of MannKind? | MannKind's last 12 months revenue is $375M. |
| What is the current revenue growth of MannKind? | MannKind revenue growth (NTM/LTM) is 28%. |
| What is the current EV/Revenue multiple of MannKind? | Current revenue multiple of MannKind is 2.0x. |
| Is MannKind profitable? | Yes, MannKind is net-income-positive (as of the last 12 months). |
| What is the current net income of MannKind? | MannKind's last 12 months net income is $4M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.